By comparing the methylation levels of whole blood samples of patients with RA who had a good or bad response to MTX therapy for weeks, it was found that the differential methylation sites related to MTX therapy were mainly near GATA3 (cg27427581), RPH3AL(cg21040096), and WDR27(cg09894276) (52). This evidence concerns the gene WDR27 and rheumatoid arthritis.